
Suzhou Basecare Medical Corporation Limited
2170.HKHKSEHealthcareMedical - Devices
Latest quote
HK$1.34
−HK$0.05 · -3.60%
2170.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteSuzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and manufacturing of genetic testing solutions specifically for assisted reproduction, alongside the distribution of related medical devices and instruments. Its extensive product line includes a range of genetic test kits for reproductive health. These comprise pre-implantation genetic tests such as PGT-A, designed to screen for chromosomal aneuploidies; PGT-M, which identifies single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits, used to detect chromosomal structural rearrangements often linked to recurrent miscarriages. Additionally, Basecare offers prenatal test kits (CNV kits) and postnatal test kits (WES kits). Complementing its genetic testing offerings, the company supplies various specialized medical equipment, including liquid nitrogen storage dewars, cryostorage systems, automated workstations, sperm quality analyzers, and next-generation sequencing (NGS) sequencers. Beyond manufacturing and sales, Basecare also provides marketing services and develops software for its medical devices and instruments. Its primary clientele consists of hospitals and reproductive clinics.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Bo Liang
- Listed since
- Feb 8, 2021
- Employees
- 407
Market position
Day range
Current HK$1.34
52-week range
Current HK$1.34
- Open
- HK$1.30
- Previous close
- HK$1.39
- Volume
- 391.5K
- 5.02× average
- Average volume
- 78K
- Average daily volume
- Market cap
- 366.52M HKD
- Beta
- 0.04
- Market reference 1
- 50-day average
- HK$1.3939
- -3.87% below average
- 200-day average
- HK$1.8074
- -25.86% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 381.26M CNY
- P/E (TTM)
- -1.4×
- P/B (TTM)
- 0.34×
- P/S (TTM)
- 1.35×
- EV / EBITDA
- -2.28×
- Earnings yield
- -48.90%
- Free cash flow yield
- -53.26%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 52.99%
- Operating margin
- -91.77%
- Net margin
- -95.79%
- Return on equity
- -23.90%
- Return on assets
- -15.44%
- Return on invested capital
- -16.33%
Financial health
- Debt / equity
- 0.37×
- Current ratio
- 3.98×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 233.27M CNY | 299.11M CNY | 207.98M CNY | 140.9M CNY | 107.3M CNY |
| Cost of goods sold | 109.66M CNY | 162.89M CNY | 116.63M CNY | 81.37M CNY | 56.15M CNY |
| Gross profit | 123.61M CNY | 136.22M CNY | 91.35M CNY | 59.53M CNY | 51.15M CNY |
| Research and development | 106.42M CNY | 135.26M CNY | 129.57M CNY | 119.77M CNY | 73.71M CNY |
| Selling, general, and administrative | 231.97M CNY | 276.39M CNY | 209.3M CNY | 161.5M CNY | 114.64M CNY |
| Operating expenses | 337.69M CNY | 367.19M CNY | 285.06M CNY | 185.65M CNY | 175.63M CNY |
| Interest income | 11.8M CNY | 25.27M CNY | 38.51M CNY | 23.62M CNY | 18.2M CNY |
| Interest expense | 13.12M CNY | 9.37M CNY | 2.61M CNY | 496K CNY | 1.26M CNY |
| Depreciation and amortization | 43.79M CNY | 14.49M CNY | 19.57M CNY | 8.39M CNY | 5.59M CNY |
| Operating income | −214.08M CNY | −230.97M CNY | −193.71M CNY | −126.12M CNY | −124.49M CNY |
| Net income | −223.46M CNY | −237.03M CNY | −191.69M CNY | −123.16M CNY | −143.65M CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.44
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Continue in GoAI
Research 2170.HKresearch.disclaimer